AR092366A1 - Derivados de (aza-)isoquinolinona - Google Patents
Derivados de (aza-)isoquinolinonaInfo
- Publication number
- AR092366A1 AR092366A1 ARP130102805A ARP130102805A AR092366A1 AR 092366 A1 AR092366 A1 AR 092366A1 AR P130102805 A ARP130102805 A AR P130102805A AR P130102805 A ARP130102805 A AR P130102805A AR 092366 A1 AR092366 A1 AR 092366A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- atoms
- hal
- phet2
- pso2n
- Prior art date
Links
- -1 tetrahidropirazolilo Chemical group 0.000 abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000002393 azetidinyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000003566 oxetanyl group Chemical group 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 abstract 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 abstract 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000005945 imidazopyridyl group Chemical group 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación. Reivindicación 1: Compuestos de la fórmula (1) donde R¹ denota F, Cl, CH₃, OCH₃, CF₃, CHF₂ o CH₂F; R² denota H o alquilo no ramificado o ramificado con 1 - 6 átomos de C; X denota C o N, siempre que sólo un X denote N; Y denota A, Cyc, [C(R²)₂]qOA, [C(R²)₂]qN(R²)₂, [C(R²)₂]ₚHet¹, [C(R²)₂]ₚCOOR², [C(R²)₂]ₚCON(R²)₂ o [C(R²)₂]ₚSO₂N(R²)₂; Ar denota fenilo, que no está sustituido o que está mono- o disustituido con Hal, A, [C(R²)₂]ₚOR, [C(R²)₂]ₚN(R²)₂, [C(R²)₂]ₚHet², NO₂, CN, [C(R²)₂]ₚCOOR, [C(R²)₂]ₚN(R²)₂, N(R²)₂COA, NR²SO₂A, [C(R²)₂]ₚSO₂N(R²)₂, S(O)ₙA, COHet², O[C(R²)₂]ₘN(R²)₂, O[C(R²)₂]ₚHet², NHCOOA, NHCON(R²)₂ o COA; Het¹ denota pirrolidinilo, azetidinilo, tetrahidroimidazolilo, tetrahidrofuranilo, oxetanilo, tetrahidropirazolilo, tetrahidropiranilo piperidinilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, piperazinilo, furilo, tienilo, pirrolilo, imidazolilo, pirazolilo, oxazolilo, isoxazolilo, oxadiazolilo, tiazolilo, triazolilo, tetrazolilo, piridilo, pirimidilo, piridazinilo, indolilo, isoindolilo, bencimidazolilo, indazolilo, quinolilo, 1,3-benzodioxolilo, benzotiofenilo, benzofuranilo, imidazopiridilo o furo[3,2-b]piridilo, cada uno de los cuales no está sustituido o está mono- o disustituido con Hal, A, [C(R²)₂]ₚOR², [C(R²)₂]ₚN(R²)₂, [C(R²)₂]ₚHet², [C(R²)₂]ₚOHet², [C(R²)₂]ₚAr, NO₂, CN, [C(R²)₂]ₚCOOR², [C(R²)₂]ₚCON(R²)₂, NR²COA, NR²SO₂A, [C(R²)₂]ₚSO₂N(R²)₂, S(O)ₙA, COHet², O[C(R²)₂]ₘN(R²)₂, O[C(R²)₂]ₚAr, O[C(R²)₂]ₚHet², NHCOOA, NHCON(R²)₂, CHO, COA, =S, =NR y/u =O; Het² denota díhidropirrolilo, pirrolidinilo, azetidinilo, oxetanilo, tetrahidroimidazolilo, dihidropirazolilo, tetrahidropirazolilo, tetrahidrofuranilo, dihidropiridilo, tetrahidropiridilo, piperidinilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, tetrahidropiranilo o piperazinilo, cada uno de los cuales no está sustituido o está mono- o disustituido con Hal, CN, OR², COOR², CON(R²)₂, S(O)ₙA, S(O)ₙAr, COA, A y/u =O; A denota alquilo no ramificado o ramificado con 1 - 10 átomos de C, en donde dos átomos de carbono adyacentes pueden formar un enlace doble y/o uno o dos grupos CH y/o CH₂ no adyacentes pueden estar reemplazados por átomos de N, O y/o S y en donde 1 - 7 átomos de H pueden estar reemplazados por F o Cl; Cyc denota cicloalquilo con 3 - 7 átomos de C, que no está sustituido o que está monosustituido con OH, Hal o A; Hal denota F, Cl, Br o I; n denota 0, 1 ó 2; m denota 1, 2 ó 3; p denota 0, 1, 2, 3 ó 4; q denota 1, 2, 3 ó 4, siempre que, cuando R¹ está ausente o metilo o metoxi, entonces Y no sea metilo, trifluorometilo, piperidinometilo, butilo, 3-metoxi-1-propilo o 4-morfolinilo; y sus solvatos, sales, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12005752 | 2012-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092366A1 true AR092366A1 (es) | 2015-04-15 |
Family
ID=48793165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102805A AR092366A1 (es) | 2012-08-08 | 2013-08-07 | Derivados de (aza-)isoquinolinona |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9376433B2 (es) |
| EP (1) | EP2882714B1 (es) |
| JP (2) | JP6247294B2 (es) |
| KR (1) | KR102083154B1 (es) |
| CN (1) | CN104507912B (es) |
| AR (1) | AR092366A1 (es) |
| AU (1) | AU2013301870B2 (es) |
| BR (1) | BR112015002601A2 (es) |
| CA (1) | CA2881330C (es) |
| DK (1) | DK2882714T3 (es) |
| ES (1) | ES2773272T3 (es) |
| HK (1) | HK1209106A1 (es) |
| HR (1) | HRP20200180T1 (es) |
| HU (1) | HUE047608T2 (es) |
| IL (1) | IL237072B (es) |
| LT (1) | LT2882714T (es) |
| MX (1) | MX362939B (es) |
| PL (1) | PL2882714T3 (es) |
| PT (1) | PT2882714T (es) |
| RS (1) | RS59921B1 (es) |
| RU (1) | RU2654216C2 (es) |
| SG (1) | SG11201500732TA (es) |
| SI (1) | SI2882714T1 (es) |
| WO (1) | WO2014023390A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104302358B (zh) | 2012-03-07 | 2017-12-05 | 癌症研究协会:皇家癌症医院 | 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途 |
| WO2014087165A1 (en) * | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
| WO2015036759A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| PT3130592T (pt) * | 2014-04-10 | 2019-11-21 | Hubei Bio Pharmaceutical Industrial Tech Institute Inc | Análogos do composto 4h-pirazolo[1,5-]benzimidazole como inibidores de parp |
| CN105153156B (zh) * | 2015-09-22 | 2017-07-28 | 徐峰 | 一种4‑苯基‑2,7‑萘啶‑1（2h）‑酮的制备方法 |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| US10759795B2 (en) | 2016-03-15 | 2020-09-01 | Purdue Research Foundation | Aza-A-ring indenoisoquinoline topoisomerase I poisons |
| WO2018078009A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2018078005A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted azaspiro derivatives as tankyrase inhibitors |
| WO2018087126A1 (en) | 2016-11-09 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives as inhibitors of tankyrase |
| US10875860B2 (en) | 2016-12-22 | 2020-12-29 | Purdue Research Foundation | Azaindenoisoquinoline compounds and uses thereof |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| RU2709928C1 (ru) * | 2019-02-21 | 2019-12-24 | Федеральное государственное бюджетное научное учреждение "Институт природно-технических систем" (ИПТС) | Датчик удельной электропроводности |
| WO2024029583A1 (ja) * | 2022-08-05 | 2024-02-08 | 国立研究開発法人理化学研究所 | 新規ピラゾール誘導体及びその用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| CN1116286C (zh) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4－苯胺基喹唑啉衍生物 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO1999011622A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| JP3989102B2 (ja) * | 1997-10-02 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合ピリジン誘導体 |
| CA2340180A1 (en) * | 1998-08-11 | 2000-02-24 | Pfizer Products Inc. | 1-aryl,-3-arylmethyl-1,8-naphthyridn-2(1h)-ones |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| PL359181A1 (en) | 2000-07-07 | 2004-08-23 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2005075432A1 (ja) * | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DK2118074T3 (en) | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| WO2008107478A1 (en) | 2007-03-08 | 2008-09-12 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp and tank inhibitors |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| FR2956816B1 (fr) | 2010-03-01 | 2012-05-18 | Univ Joseph Fourier | Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104302358B (zh) * | 2012-03-07 | 2017-12-05 | 癌症研究协会:皇家癌症医院 | 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途 |
| US20130311482A1 (en) | 2012-05-17 | 2013-11-21 | Tagged, Inc. | Multi-user timeline for facilitating social discovery in social networking environments |
-
2013
- 2013-07-12 SG SG11201500732TA patent/SG11201500732TA/en unknown
- 2013-07-12 AU AU2013301870A patent/AU2013301870B2/en not_active Ceased
- 2013-07-12 CA CA2881330A patent/CA2881330C/en active Active
- 2013-07-12 DK DK13737146.4T patent/DK2882714T3/da active
- 2013-07-12 JP JP2015525763A patent/JP6247294B2/ja not_active Expired - Fee Related
- 2013-07-12 SI SI201331671T patent/SI2882714T1/sl unknown
- 2013-07-12 PL PL13737146T patent/PL2882714T3/pl unknown
- 2013-07-12 CN CN201380041848.2A patent/CN104507912B/zh not_active Expired - Fee Related
- 2013-07-12 EP EP13737146.4A patent/EP2882714B1/en active Active
- 2013-07-12 MX MX2015001545A patent/MX362939B/es active IP Right Grant
- 2013-07-12 HU HUE13737146A patent/HUE047608T2/hu unknown
- 2013-07-12 RU RU2015107702A patent/RU2654216C2/ru active
- 2013-07-12 WO PCT/EP2013/002085 patent/WO2014023390A2/en active Application Filing
- 2013-07-12 BR BR112015002601A patent/BR112015002601A2/pt not_active Application Discontinuation
- 2013-07-12 ES ES13737146T patent/ES2773272T3/es active Active
- 2013-07-12 US US14/420,578 patent/US9376433B2/en not_active Expired - Fee Related
- 2013-07-12 RS RS20200154A patent/RS59921B1/sr unknown
- 2013-07-12 KR KR1020157005977A patent/KR102083154B1/ko active IP Right Grant
- 2013-07-12 LT LTEP13737146.4T patent/LT2882714T/lt unknown
- 2013-07-12 PT PT137371464T patent/PT2882714T/pt unknown
- 2013-08-07 AR ARP130102805A patent/AR092366A1/es unknown
-
2015
- 2015-02-03 IL IL237072A patent/IL237072B/en active IP Right Grant
- 2015-10-05 HK HK15109706.9A patent/HK1209106A1/xx not_active IP Right Cessation
-
2017
- 2017-07-21 JP JP2017142160A patent/JP6333450B2/ja active Active
-
2020
- 2020-02-04 HR HRP20200180TT patent/HRP20200180T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092366A1 (es) | Derivados de (aza-)isoquinolinona | |
| AR090896A1 (es) | DERIVADOS DE PIRROLOTRIAZINONA COMO INHIBIDORES DE TANKs Y PARP-1 | |
| AR090496A1 (es) | Derivados biciclicos de pirazinona | |
| AR090240A1 (es) | Derivados de triazolopirazina | |
| AR094981A1 (es) | Derivados de imidazopirimidinas | |
| AR089945A1 (es) | DERIVADOS DE FURO[3,2-B] Y TIENO[3,2-B]PIRIDINA COMO MODULADORES DE TBK1 E IKKe | |
| AR092670A1 (es) | Derivados de quinazolinona | |
| AR089810A1 (es) | Derivados de triazolo[4,5-d]pirimidina | |
| AR100333A1 (es) | Derivados de heterociclil-butanamida | |
| AR087807A1 (es) | Derivados de benzonitrilo | |
| AR094982A1 (es) | Derivados de triazolo[4,5-d]pirimidina | |
| AR088925A1 (es) | Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina | |
| AR094857A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| AR068658A1 (es) | Derivados de tiazol | |
| AR092211A1 (es) | Derivados de hidropirrolopirrol | |
| AR097087A1 (es) | Derivados de oxoquinazolinil-butanamida | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR093512A1 (es) | Derivados heterociclicos como moduladores de la actividad de cinasas | |
| AR092365A1 (es) | Derivados de piridopirimidina | |
| AR095530A1 (es) | Moduladores de p2x7 | |
| AR091939A1 (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR097086A1 (es) | Derivados 1,3-disustituidos de ciclopentano | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |